# A Study to Investigate the Safety, Tolerability and Pharmacokinetics of Single and Repeat Doses of PC945

> **NCT02715570** · PHASE1 · COMPLETED · sponsor: **Pulmocide Ltd** · enrollment: 29 (actual)

## Conditions studied

- Aspergillosis

## Interventions

- **DRUG:** PC945 - single doses
- **DRUG:** Placebo - single doses
- **DRUG:** PC945 - repeat doses
- **DRUG:** Placebo - repeat doses

## Key facts

- **NCT ID:** NCT02715570
- **Lead sponsor:** Pulmocide Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-10-23
- **Primary completion:** 2018-04-27
- **Final completion:** 2018-04-27
- **Target enrollment:** 29 (ACTUAL)
- **Last updated:** 2018-05-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02715570

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02715570, "A Study to Investigate the Safety, Tolerability and Pharmacokinetics of Single and Repeat Doses of PC945". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02715570. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*